US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Lydall

62.09

0.0000

Volume:- -

Turnover:14.15M

Market Cap:1.12B

PE:-1.89K

High:62.09

Open:62.09

Low:62.09

Close:62.09

52wk High:62.12

52wk Low:16.10

Shares:18.04M

Float Shares:17.00M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0328

EPS(LYR):-4.2422

ROE:-0.22%

ROA:3.14%

PB:4.07

PE(LYR):-14.64

Loading ...

Overview Company News Filings

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial

Benzinga_recent_news

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

The Hidden Genetic Threat Putting 1 in 5 at Cardiovascular Disease Risk: Global Experts Call for Action on Elevated Lipoprotein(a)

Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LDL/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LDL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LDL\",,,,,undefined,":{"symbol":"LDL","market":"US","secType":"STK","nameCN":"Lydall","latestPrice":62.09,"timestamp":1633032000000,"preClose":62.09,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":16998398,"shares":18037202,"eps":-0.032776,"marketStatus":"Delisted","change":0,"latestTime":"02-11 13:08:59 EST","open":62.09,"high":62.09,"low":62.09,"amount":14149344.710749999,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.032776,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770843600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":62.09,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LDL\",,,,,undefined,":{"symbol":"LDL","floatShares":16998398,"roa":"3.14%","roe":"-0.22%","lyrEps":-4.242188,"shares":18037202,"dividePrice":0,"high":62.09,"amplitude":0,"preClose":62.09,"low":62.09,"week52Low":16.1,"pbRate":"4.07","week52High":62.12,"institutionHeld":0.9097,"latestPrice":62.09,"eps":-0.032776,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.032776,"open":62.09},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LDL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2021-10-01","symbol":"LDL","reason":null,"defaultRemindTime":1633095000000,"announcedDate":"2021-09-28","type":"delisting","dateTimestamp":1633060800000},{"market":"US","date":"2021-07-28","symbol":"LDL","fiscalQuarterEnding":"2021/06","expectedEps":0.41,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1627444800000,"reportTimeType":"post","actualEps":0.5},{"market":"US","date":"2021-04-27","symbol":"LDL","fiscalQuarterEnding":"2021/03","expectedEps":0.19,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1619496000000,"reportTimeType":"post","actualEps":0.35},{"market":"US","date":"2021-02-23","symbol":"LDL","fiscalQuarterEnding":"2020/12","expectedEps":0.07,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1614056400000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2020-10-27","symbol":"LDL","fiscalQuarterEnding":"2020/09","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1603771200000,"reportTimeType":"post","actualEps":-0.02}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LDL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LDL\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LDL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LDL","date":"2021-09-29","current":-1894.373932,"percent":0.006426,"low":-1953.243253,"twenty":-2.569621,"median":9.95639,"eighty":22.034281,"high":104.179034,"avg":-56.795719,"sd":348.820357,"marketCap":1117945779},"quantilePoints":[{"date":"2021-02-12","current":-4.09793,"twenty":6.907641,"median":17.377135,"eighty":22.459379,"marketCap":591941860},{"date":"2021-02-19","current":-3.951838,"twenty":6.868046,"median":17.298589,"eighty":22.435777,"marketCap":570839079},{"date":"2021-02-26","current":-8.100969,"twenty":6.691665,"median":17.238524,"eighty":22.405647,"marketCap":597243951},{"date":"2021-03-05","current":-8.946435,"twenty":-1.274748,"median":17.132064,"eighty":22.342913,"marketCap":659575930},{"date":"2021-03-12","current":-9.774142,"twenty":-1.463876,"median":17.05834,"eighty":22.273012,"marketCap":720598600},{"date":"2021-03-19","current":-8.962482,"twenty":-1.499449,"median":17.007728,"eighty":22.25825,"marketCap":660758996},{"date":"2021-03-26","current":-8.241279,"twenty":-1.567618,"median":16.852548,"eighty":22.222118,"marketCap":607588264},{"date":"2021-04-01","current":-8.248613,"twenty":-1.58113,"median":16.821512,"eighty":22.205307,"marketCap":608128983},{"date":"2021-04-09","current":-7.867231,"twenty":-1.635945,"median":16.552533,"eighty":22.160788,"marketCap":580011579},{"date":"2021-04-16","current":-7.784109,"twenty":-1.689041,"median":15.65042,"eighty":22.132957,"marketCap":573883427},{"date":"2021-04-23","current":-7.965021,"twenty":-1.730493,"median":14.562091,"eighty":22.095979,"marketCap":587221170},{"date":"2021-04-30","current":-54.470197,"twenty":-1.788356,"median":13.39391,"eighty":22.062043,"marketCap":665081105},{"date":"2021-05-07","current":-57.480742,"twenty":-1.828392,"median":12.819937,"eighty":22.057011,"marketCap":701839855},{"date":"2021-05-14","current":-54.263591,"twenty":-1.849146,"median":12.597753,"eighty":22.057011,"marketCap":662558446},{"date":"2021-05-21","current":-51.208774,"twenty":-1.909275,"median":12.371846,"eighty":22.057011,"marketCap":625259126},{"date":"2021-05-28","current":-54.411167,"twenty":-2.015562,"median":12.10128,"eighty":22.057011,"marketCap":664360345},{"date":"2021-06-04","current":-53.304349,"twenty":-2.091329,"median":11.996545,"eighty":22.057011,"marketCap":650846099},{"date":"2021-06-11","current":-52.979682,"twenty":-2.126479,"median":11.835078,"eighty":22.057011,"marketCap":646881920},{"date":"2021-06-18","current":-50.884107,"twenty":-2.192525,"median":11.542692,"eighty":22.057011,"marketCap":621294947},{"date":"2021-06-25","current":-127.95469,"twenty":-2.206817,"median":11.356204,"eighty":22.057307,"marketCap":1562326760},{"date":"2021-07-02","current":-89.304461,"twenty":-2.241141,"median":11.273483,"eighty":22.057307,"marketCap":1090407467},{"date":"2021-07-09","current":-89.52595,"twenty":-2.288538,"median":11.16597,"eighty":22.057307,"marketCap":1093111851},{"date":"2021-07-16","current":-89.776971,"twenty":-2.310087,"median":11.032127,"eighty":22.057307,"marketCap":1096176819},{"date":"2021-07-23","current":-90.342289,"twenty":-2.324221,"median":10.97508,"eighty":22.057307,"marketCap":1103079344},{"date":"2021-07-30","current":-1928.556675,"twenty":-2.350235,"median":10.879369,"eighty":22.064115,"marketCap":1105062975},{"date":"2021-08-06","current":-1931.703798,"twenty":-2.384531,"median":10.766637,"eighty":22.064115,"marketCap":1106866276},{"date":"2021-08-13","current":-1940.966623,"twenty":-2.401492,"median":10.611925,"eighty":22.064115,"marketCap":1112173875},{"date":"2021-08-20","current":-1942.225764,"twenty":-2.429806,"median":10.487285,"eighty":22.064115,"marketCap":1112895363},{"date":"2021-08-27","current":-1943.799691,"twenty":-2.446597,"median":10.39144,"eighty":22.068261,"marketCap":1113797223},{"date":"2021-09-03","current":-1951.984112,"twenty":-2.484784,"median":10.308062,"eighty":22.068261,"marketCap":1118486896},{"date":"2021-09-10","current":-1948.836257,"twenty":-2.50254,"median":10.189862,"eighty":22.068261,"marketCap":1116683175},{"date":"2021-09-17","current":-1950.095398,"twenty":-2.523075,"median":10.093855,"eighty":22.068261,"marketCap":1117404663},{"date":"2021-09-24","current":-1950.724969,"twenty":-2.558669,"median":10.008758,"eighty":22.057897,"marketCap":1117765407},{"date":"2021-09-29","current":-1951.039754,"twenty":-2.569621,"median":9.95639,"eighty":22.034281,"marketCap":1117945779}],"updateTime":1770833339952},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LDL\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2602543576","title":"CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543576","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543576?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:36","pubTimestamp":1768224960,"startTime":"0","endTime":"0","summary":"-2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY launch acceleration continues, supporting multi-billion-dollar potential- -Broad pipeline supported by leading gene","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216929/0/en/CRISPR-Therapeutics-Highlights-Strategic-Priorities-and-Anticipated-2026-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0251142724.SGD","LU2237438978.USD","BK4022","CRSP","BK4520","BK4199","LU0742534661.SGD","LU1988902786.USD","FXI","BK4153","BK4090","BK4532","LU0868494617.USD","TG","SCD","LU0048573561.USD","AGT","LU1861558580.USD","LU1917777945.USD","BK4556","LU0942090050.USD","LU1974910355.USD","LU1720051108.HKD","LU2357305700.SGD","CAR","CAT","LU1548497426.USD","ITP","LU0963586101.USD","LU2023250504.SGD","BK4611","BK4597","BK4077","LDL","BK4516","LU0868494708.USD","LU1861559042.SGD","BK4139","IE00BD6J9T35.USD","BK4230","LU0251131958.USD","SLE","LU2106854487.HKD","BK4588","BK4149","BK4504","IE00BSNM7G36.USD","LU1064131342.USD","LU1720051017.SGD","LU2264538146.SGD"],"gpt_icon":0},{"id":"2592967216","title":"Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol","url":"https://stock-news.laohu8.com/highlight/detail?id=2592967216","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592967216?lang=en_us&edition=fundamental","pubTime":"2025-12-17 16:10","pubTimestamp":1765959000,"startTime":"0","endTime":"0","summary":"LEROCHOL is a novel, third-generation PCSK9 inhibitor designed to help patients achieve and maintain their LDL-C targets. It is self-administered as a once-monthly, single small-volume subcutaneous injection with extended room-temperature stability , giving patients the freedom to administer it where and when they choose. These features make LEROCHOL a unique alternative to other PCSK9 inhibitors.The FDA approval of LEROCHOL was based on data from the comprehensive global Phase 3 LIBerate Clinical Trial Program, which enrolled a diverse population of over 2,900 patients with cardiovascular disease , or without but at very high or high risk for CVD, including HeFH.In clinical trials, LEROCHOL demonstrated sustained LDL-C reductions of ≥60% in patients with, or at very-high or high risk of CVD and 59% in those with HeFH who have more severe LDL-C elevations. LEROCHOL was generally well tolerated across the LIBerate Clinical Trial Program. Lerodalcibep is expected to expand treatment opti","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/everest-medicines-announces-that-licensing-partner-lib-therapeutics-has-received-us-fda-approval-of-lerochol-lerodalcibep-liga-for-adults-with-elevated-ldl-cholesterol-302644459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLA.AU","BK4539","BK7129","LDL","LENZ","BK4139","BK4007","BK4081","EMA.AU","MDCO","EMA"],"gpt_icon":0},{"id":"2582046360","title":"CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2582046360","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582046360?lang=en_us&edition=fundamental","pubTime":"2025-11-11 22:50","pubTimestamp":1762872600,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its gene editing platform.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/11/Gene-therapy-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/11/Gene-therapy-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/11/48779688/crispr-therapeutics-investigational-gene-therapy-shows-promising-lipid-lowering-effects-in-early-trial","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/11/48779688/crispr-therapeutics-investigational-gene-therapy-shows-promising-lipid-lowering-effects-in-early-trial","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU1861559042.SGD","LU1974910355.USD","LU2106854487.HKD","BK4585","LU2362541513.USD","LU2089984988.USD","LU0053666078.USD","LU0823434583.USD","LU0289739699.SGD","LU2362541273.HKD","USJW.SI","TG","TSYW.SI","LU0889565916.HKD","LU2468319806.SGD","LU2237438978.USD","BK4153","REGN","LDL","MNQmain","BK4139","BK4090","BK4611","LU0320765992.SGD","ARWR","LU0882574055.USD","LU1917777945.USD","NVIW.SI","USAW.SI","LU2362540622.SGD","NQmain","LU0823434740.USD","LU1861558580.USD","PSQ","TQQQ","LU0109394709.USD",".IXIC","SQQQ","LU0058720904.USD","LU2023250504.SGD","BK4588","LU0114720955.EUR","LU0823416689.USD","QID","BK4556","QLD","CRSP"],"gpt_icon":1},{"id":"2582872883","title":"CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2582872883","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582872883?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:00","pubTimestamp":1762779600,"startTime":"0","endTime":"0","summary":"-Positive Phase 1 data for CTX310 presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Medic","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/10/3184507/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0061475181.USD","LU1559883803.SGD","SLE","LDL","ASH","LU1035775433.USD","LU0566484027.USD","LU1778281490.HKD","LU2362540622.SGD","CAR","AHP","TG","LU0889565916.HKD","SCD","VERX","LU1585245621.USD","UAE","LU1917777945.USD","IE00B2B36J28.USD","IE00B19Z3581.USD","BK4149","LU1430594728.SGD","LU2463526074.USD","CAT","BK4597","MACE","LU2236285917.USD","BK4109","LU2456880835.USD","LU0963586101.USD","IE0009355771.USD","CRSP","BK4230","LU0079474960.USD","LU0942090050.USD","FXI","LU1988902786.USD","BK4588","LU0234570918.USD","KSA","LU2324357040.USD","IE00BZ9MQY76.HKD","LU0417517546.SGD","LU1674673428.USD","LU1861559042.SGD","LU2237438978.USD","VRTX","BK4153","LU0432979614.USD","LU1674673691.USD"],"gpt_icon":0},{"id":"2569770573","title":"The Hidden Genetic Threat Putting 1 in 5 at Cardiovascular Disease Risk: Global Experts Call for Action on Elevated Lipoprotein(a)","url":"https://stock-news.laohu8.com/highlight/detail?id=2569770573","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569770573?lang=en_us&edition=fundamental","pubTime":"2025-09-24 18:12","pubTimestamp":1758708720,"startTime":"0","endTime":"0","summary":"Cardiovascular disease  kills nearly 18 million people each year, more than all cancers combined1,2. Elevated lipoprotein orLp, an inherited condition that raises CVD risk, affects 1 in 5 people worldwide but is rarely tested3. New survey across Asia Pacific and Middle East shows 66% skip routine heart checks and nearly half are unaware of the genetic link to heart disease. Experts urge audience to prioritizeLp in cardiovascular strategies, bridging awareness gaps and driving equitable access to testing and care. SINGAPORE, Sept. 24, 2025 /PRNewswire/ -- Cardiovascular disease  kills nearly 18 million people every year, more than all cancers combined,yet one of its critical genetic risk factors remains largely invisible.1,2 Elevated lipoprotein, or Lp, the \"little a with big consequences,\" affects 1 in 5 people globally but is rarely tested and often overlooked in heart health strategies.3,4. Policy Lens: Nicola Bedlington, Senior Policy Advisor/Project Lead, Lp International Task Forc","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2780864/Novartis___GHH_logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2780864/Novartis___GHH_logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/the-hidden-genetic-threat-putting-1-in-5-at-cardiovascular-disease-risk-global-experts-call-for-action-on-elevated-lipoproteina-302565695.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSII","MNDmain","LDL","BK4082"],"gpt_icon":0},{"id":"2563889119","title":"Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2563889119","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563889119?lang=en_us&edition=fundamental","pubTime":"2025-08-30 23:00","pubTimestamp":1756566000,"startTime":"0","endTime":"0","summary":"V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C) goals early with reduced muscle pain1 85% of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/30/3141878/0/en/Novartis-Leqvio-shows-statistically-significant-and-clinically-meaningful-early-LDL-C-goal-achievement-with-less-muscle-pain.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","HCP","LDL","BK4588","BK4023"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}]}}